GPC3-CAR-T cell therapy

Drug Profile

GPC3-CAR-T cell therapy

Alternative Names: anti-GPC3 CAR T; CAR-GPC3 T-cell; Glypican-3-chimeric-antigen-receptor-T-cell-therapy; GPC3-CAR/CSG-GPC3

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CARsgen
  • Developer CARsgen; Shanghai Jiao Tong University
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast cancer; Gastric cancer; Lung cancer
  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Hepatocellular carcinoma(In the elderly, Late-stage disease, Refractory metastatic disease, In adults) in China (Parenteral)
  • 05 Oct 2017 Carsgen plans a phase I trial for GPC3-CAR-T cell therapy for Hepatocellular carcinoma (In adults, In the elderly) in China (NCT03302403)
  • 05 Jun 2017 Preliminary efficacy and adverse events data from a phase I trial in Hepatocellular carcinoma released by CARsgen Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top